Does lopinavir measure up in the treatment of COVID-19?

ABSTRACT:

Introduction

Lopinavir in combination with ritonavir is approved for the treatment of HIV and has recently been subject to a clinical trial in severe COVID-19.

Areas covered

This evaluation is of LOTUS China (the Lopinavir Trial for Suppression of SARS-Cov-2 in China), which was a randomized trial in hospitalized subjects with COVID-9 in a respiratory sample and pneumonia. As, in severe COVID-19, lopinavir/ritonavir had no beneficial effects but increased gastrointestinal adverse effects, this combination should not be used at this stage of COVID-19.

Expert opinion

In my opinion, the rationale for undertaking a trial of lopinavir/ritonavir in COVID-19 was poor. The analysis of a modified intention to treat group analysis in LOTUS China may have introduced bias. After

SUBMITTER: Doggrell SA 

PROVIDER: S-EPMC7441752 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature